80 related articles for article (PubMed ID: 24294969)
41. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
[TBL] [Abstract][Full Text] [Related]
42. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.
Shultz MD; Cheung AK; Kirby CA; Firestone B; Fan J; Chen CH; Chen Z; Chin DN; Dipietro L; Fazal A; Feng Y; Fortin PD; Gould T; Lagu B; Lei H; Lenoir F; Majumdar D; Ochala E; Palermo MG; Pham L; Pu M; Smith T; Stams T; Tomlinson RC; Touré BB; Visser M; Wang RM; Waters NJ; Shao W
J Med Chem; 2013 Aug; 56(16):6495-511. PubMed ID: 23844574
[TBL] [Abstract][Full Text] [Related]
43. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
44. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
45. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
[TBL] [Abstract][Full Text] [Related]
46. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
47. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
48. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
49. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
50. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
51. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
52. The telomeric PARP, tankyrases, as targets for cancer therapy.
Seimiya H
Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
[TBL] [Abstract][Full Text] [Related]
53. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
54. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
55. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
56. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
57. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.
Riffell JL; Lord CJ; Ashworth A
Nat Rev Drug Discov; 2012 Dec; 11(12):923-36. PubMed ID: 23197039
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
